Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches
Pseudoxanthoma elasticum (PXE) is an inherited disorder that is associated with
accumulation of mineralized and fragmented elastic fibers in the skin, vascular walls, and …
accumulation of mineralized and fragmented elastic fibers in the skin, vascular walls, and …
Bevacizumab for neovascular ocular diseases
SS Lynch, CM Cheng - Annals of Pharmacotherapy, 2007 - journals.sagepub.com
Objective: To review the efficacy and safety of off-label use of bevacizumab for neovascular
ocular diseases. Data Sources: A PubMed (1966–January 2007) search was conducted …
ocular diseases. Data Sources: A PubMed (1966–January 2007) search was conducted …
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans
PURPOSE: To investigate intraocular concentrations and pharmacokinetics of bevacizumab
after a single intravitreal injection in humans. DESIGN: Prospective, noncomparative …
after a single intravitreal injection in humans. DESIGN: Prospective, noncomparative …
Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months
PURPOSE: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy
Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal …
Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal …
Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration
R Lazic, N Gabric - Graefe's Archive for Clinical and Experimental …, 2007 - Springer
Background Anti-vascular endothelial growth factor (anti-VEGF) agents have been shown to
be effective in the treatment of neovascular age-related macular degeneration (AMD) …
be effective in the treatment of neovascular age-related macular degeneration (AMD) …
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
CI Sinapis, JG Routsias, AI Sinapis… - Clinical …, 2011 - Taylor & Francis
Purpose: To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits.
Methods: The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL …
Methods: The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL …
A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
JSAG Schouten, EC La Heij, CAB Webers… - Graefe's Archive for …, 2009 - Springer
Aim To provide evidence for the effect of bevacizumab on visual acuity (VA) and central
retinal thickness (CRT) in exudative age-related macular degeneration Methods A …
retinal thickness (CRT) in exudative age-related macular degeneration Methods A …
Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial
SG Priglinger, AH Wolf, TC Kreutzer, D Kook, A Hofer… - Retina, 2007 - journals.lww.com
Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin; Genentech, Inc., South
San Francisco, CA) injections on visual acuity and foveal retinal thickness in patients with …
San Francisco, CA) injections on visual acuity and foveal retinal thickness in patients with …
Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective …
Purpose: To assess the effectiveness of consecutive intravitreal injections of recombined
tissue plasminogen activator (rtPA), expansile gas and bevacizumab in eyes with acute …
tissue plasminogen activator (rtPA), expansile gas and bevacizumab in eyes with acute …
Current treatment approaches in diabetic macular edema
CH Meyer - Ophthalmologica, 2007 - karger.com
Purpose: To review current treatment approaches in diabetic macular edema (DME).
Methods: The underlying pathopathology, classifications and diagnostic examination …
Methods: The underlying pathopathology, classifications and diagnostic examination …